PRESS CONFERENCE SCHEDULE
Conference on Retroviruses and Opportunistic Infections/CROI 2016
All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET.

Monday, February 22, 2:00 – 3:00 pm

2:00 – 2:20 PM Chaired by Julie M. Overbaugh, CROI Chair and Fred Hutchinson Cancer Research Center, Seattle, WA, US

WELCOME AND OVERVIEW OF CROI 2016
Julie M. Overbaugh, CROI Chair and Fred Hutchinson Cancer Research Center, Seattle, WA, US
Susan P. Buchbinder, CROI Vice Chair and University of California San Francisco, CA, US
– and –
Judith Currier, CROI Vice Chair and University of California Los Angeles, CA, US

2:20 – 2:40 PM Chaired by Kevin M. De Cock, CDC, Nairobi, Kenya

SPECIAL SESSION – EBOLA: ONE YEAR LATER
(PRESENTED TUESDAY, FEBRUARY 23, 6:15 PM - 7:45 PM)
(EMBARGO ON THESE STUDIES LIFTS MONDAY, FEBRUARY 22, 2:40 PM ET)

73LB. Sequelae of Ebola Virus Disease in Surviving Patients in Guinea: Postebogui Cohort
Eric Delaporte, UMI 233-IRD/U1175-INSERM/Montpellier University, Montpellier, France

75LB. Dynamics of Ebola Virus Clearance in Semen in Guinea
Daouda Sissoko, INSERM U897, Bordeaux, France

2:40 – 3:00 PM Chaired by Wafaa El-Sadr, ICAP at Columbia University, New York, NY, US

ORAL ABSTRACT SESSION 9 – EXPANDING THE TOOLBOX FOR PREVENTION
(PRESENTED WEDNESDAY, FEBRUARY 24, 10:00 AM – 12:00 PM)
(EMBARGO ON THESE STUDIES LIFTS MONDAY, FEBRUARY 22, 3:00 PM ET)

109LB. A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women
Jared M. Baeten, University of Washington, Seattle, WA, US

110LB. Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women
Annalene Nel, International Partnership for Microbicides, Paarl, South Africa
Conference on Retroviruses and Opportunistic Infections/CROI 2016

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET.

Tuesday, February 23, 12:30 – 1:30 pm

12:30 – 1:00 PM

Chaired by John Coffin, Tufts University, Medford, MA, US

- and -

Susan P. Buchbinder, University of California San Francisco, CA, US

**ORAL ABSTRACT SESSION 1 – SIV AND HIV PATHOGENESIS**
(PRESENTED TUESDAY, FEBRUARY 23, 10:00 AM - 12:00 PM)

18LB. HIV-1 Laboratory Contagion During Recombination Procedures With Defective Constructs
Claudia Alteri, University of Rome Tor Vergata, Rome, Italy

**ORAL ABSTRACT SESSION 5 – STRATEGIES FOR TESTING AND LINKAGE TO CARE: ARE WE CLOSING THE GAP?**
(PRESENTED TUESDAY, FEBRUARY 23, 10:00 AM - 12:00 PM)

52. Estimating the Lifetime Risk of a Diagnosis of HIV Infection in the United States
Kristen Hess, US Centers for Disease Control and Prevention, Atlanta, GA, US

53. Increased HIV Viral Suppression Among US Adults Receiving Medical Care, 2009-2013
Heather Bradley, US Centers for Disease Control and Prevention, Atlanta, GA, US

54. Narrowing the Gap in Life Expectancy for HIV+ Compared With HIV- Individuals
Julia L. Marcus, Kaiser Permanente Northern California, Oakland, CA, US

55. Perception of Infectiousness in HIV-Infected Persons After Initiating ART: ACTG A5257
Raphael J. Landovitz, David Geffen School of Medicine, University of California Los Angeles, CA

1:00 – 1:30 PM

Chaired by Elaine J. Abrams, Columbia University, New York, NY, US

**ORAL ABSTRACT SESSION 3 – PREVENTION AND TREATMENT OF PEDIATRIC HIV INFECTIONS**
(PRESENTED TUESDAY, FEBRUARY 23, 10:00 AM - 12:00 PM)

34. Impact of Option B+ on ART Uptake and Retention in Swaziland: A Stepped-Wedge Trial
Harriet Nuwagaba-Biribonwoha, ICAP, Columbia University Mailman School of Public Health, New York, NY, US

35LB. National HIV Transmission in 4-12 Week Olds in Malawi’s PMTCT Option B+ Program
Sundeep Gupta, CDC, Harare, Zimbabwe

36. Impact of Maternal Tenofovir Use on HIV-Exposed Newborn Bone Mineral
George K. Siberry, Eunice Kennedy Shriver NICHD, Bethesda, MD, US

37. Similar Mortality With Cotrimoxazole vs Placebo in HIV-Exposed Uninfected Children
Roger L. Shapiro, Harvard School of Public Health, Boston, MA, US
Conference on Retroviruses and Opportunistic Infections/CROI 2016

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET.

Wednesday, February 24, 12:30 – 1:30 pm

12:30 – 1:00 PM

Chaired by Diane Havlir, University of California San Francisco, CA, US

**ORAL ABSTRACT SESSION 10 – GETTING TO 90-90-90**
(PRESENTED WEDNESDAY, FEBRUARY 24, 10:00 AM - 12:00 PM)

Tendani Gaolathe, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana

112. Streamlining Antiretroviral Therapy Uptake: A Stepped-Wedge Cluster Randomized Trial
Gideon Amanyire, Makerere University College of Health Sciences, Kampala, Uganda

117. HIV Mortality by Care Cascade Stage and Implications for Universal ART Eligibility
Jeffrey Eaton, Imperial College London, London, UK

**SYMPOSIUM SESSION 5 – REACHING 90-90-90 AND BEYOND: CHALLENGES AND INNOVATIONS**
(PRESENTED WEDNESDAY, FEBRUARY 24, 4:00 PM - 6:00 PM)
(EMBARGO ON THESE PRESENTATIONS LIFTS WEDNESDAY, FEBRUARY 24, 1:00 PM ET)

120. Missing But in Action: Where Are the Men?
Helen Ayles, London School of Hygiene & Tropical Medicine, London, UK

122. Innovations in Antiretroviral Therapy Delivery
Anna Grimsrud, International AIDS Society, Cape Town, South Africa

1:00 – 1:30 PM

Sharon L. Hillier, University of Pittsburgh School of Medicine, Magee-Womens Hospital PA, US

**ORAL ABSTRACT SESSION 9 – EXPANDING THE TOOLBOX FOR PREVENTION**
(PRESENTED WEDNESDAY, FEBRUARY 24, 10:00 AM - 12:00 PM)

106. ÉCLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV Uninfected Men
Martin Markowitz, Aaron Diamond AIDS Research Center, New York, NY, US

**THEMED DISCUSSION SESSION 12 – IT’S COMPLICATED: RENAL FUNCTION AND STIS IN PREP USERS**
(PRESENTED WEDNESDAY, FEBRUARY 24, 1:45 PM - 2:45 PM)
(EMBARGO ON THESE STUDIES LIFTS WEDNESDAY, FEBRUARY 24, 1:30 PM ET)

866. Higher Cumulative TFV/FTC Levels in PrEP Associated With Decline in Renal Function
Monica Gandhi, University of California San Francisco, San Francisco, CA, US

867. Changes in Renal Function Associated With TDF/FTC PrEP Use in the US Demo Project

869. STI Data From Community-Based PrEP Implementation Suggest Changes to CDC Guidelines
Sarit A. Golub, Hunter College, City University of New York, NY, US
Conference on Retroviruses and Opportunistic Infections/CROI 2016

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET.

Wednesday, February 24, 12:30 – 1:30 pm

POSTER ABSTRACT SESSION 3 – PREDICTORS OF PrEP COVERAGE AND UPTAKE
(PRESENTED THURSDAY, FEBRUARY 25, 2:45 PM - 4:00 PM)
(EMBARGO ON THIS STUDY LIFTS WEDNESDAY, FEBRUARY 24, 1:30 PM ET)

883LB. HPTN 073: PrEP Uptake and Use by Black Men Who Have Sex With Men in 3 US Cities
Durrell P. Wheeler, State University of New York at Albany, NY, US
Conference on Retroviruses and Opportunistic Infections/CROI 2016

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are ET

Thursday, February 25, 12:30 – 1:30pm

12:30 – 12:50 PM  Chaired by Harold W. Jaffe, US Centers for Disease Control and Prevention, Atlanta, GA, US

**PLENARY SESSION 6 – THE EVOLVING EPIDEMIOLOGY OF HIV INFECTION IN PERSONS WHO INJECT DRUGS: INDIANA 2015**
(PRESENTED THURSDAY, FEBRUARY 25, 9:00 AM - 9:30 AM)

132. The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015
John Brooks, US Centers for Disease Control and Prevention, Atlanta, GA, US

**ORAL ABSTRACT SESSION 13 – HCV: CURING THE PATIENT BUT NOT THE POPULATION**
(PRESENTED THURSDAY, FEBRUARY 25, 10:00 AM - 12:00 PM)

Sumathi Ramachandran, US Centers for Disease Control and Prevention, Atlanta, GA, US

12:50 – 1:30 PM  Chaired by Richard Chaisson, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, MA, US

**ORAL ABSTRACT SESSION 14 – TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS/CANCER PREVENTION: HITS AND MISSES**
(PRESENTED THURSDAY, FEBRUARY 25, 10:00 AM - 12:00 PM)

155. Empirical TB Treatment in Advanced HIV Disease: Results of the TB Fast Track Trial
Alison Grant, London School of Hygiene & Tropical Medicine, London, UK

156. Acceptability of Large-Scale Household-Based TB Screening: HPTN 071 (PopART)
Comfort R. Phiri, ZAMBART, Lusaka, Zambia

157. HIV-Associated XDR TB Is Transmitted in Households and Hospitals in South Africa
Sara C. Auld, Emory University, Atlanta, GA, US

159. Pre-ART Cryptococcal Antigen Titer Associated With Preemptive Fluconazole Failure
Bozena M. Morawski, University of Minnesota, Minneapolis, MN, US